ERBB2 and breast cancer: Among these, 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18FDG-PET) has demonstrated utility in evaluating treatment response, particularly in HR-positive/HER2-negative and triple negative BC [31–41].